Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JNJ-74856665 (DHODH inhibitor) in AML and MDS
NCT04609826Phase 1Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2020
- Primary completion
- Aug 2025
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 1, open-label trial of JNJ-74856665 in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (4 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Dose-Limiting Toxicity at 28 days, Adverse Events at 6 months and 1 more. Started Nov 2020; status: completed.
02
Drugs
JNJ-74856665
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT04609826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609826.